Erasca, Inc.
ERAS-007
Advanced or Metastatic Solid Tumors
Countdown
117days
Phase 2 readout · Nov 1, 2026
What's at stake
Phase 2 trial results for ERAS-007 in Advanced or Metastatic Solid Tumors are due Nov 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT04866134: Phase 2 trial, sponsor Erasca, Inc., drug ERAS-007. Primary completion date 2026-11-01 (estimated).”